MEDVi
US$ 29.74
soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 Heart disease is the #1 cause of death in type 2 diabetes — and for the first time, an GLP-1 drug has been proven to reduce major events The Oral Semaglutide Reduces CV Events
Description
There are...
Novartis ~$30B+ dealmaking to strengthen pipeline New drug launches driving growth Heavy investment in oncology + cardiovascular Trend: More capital more late-stage assets rising demand for clinical leadership
As a scientist, its exciting to conduct research at this scaleusing millions of real-world data points to uncover measurable patterns and actionable insights
GLP-1 receptor agonist studied for metabolic & glycemic research
There is growing evidence that Ozempic and other GLP-1 receptor agonist drugs might help people drink less alcohol, but more research is needed.
